Technical Analysis for AMRX - Amneal Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.65 -2.93% -0.08
AMRX closed down 2.93 percent on Monday, November 11, 2019, on 70 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AMRX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -2.93%
Stochastic Reached Oversold Weakness -2.93%
Wide Bands Range Expansion -2.93%
Oversold Stochastic Weakness -2.93%
MACD Bearish Centerline Cross Bearish 0.00%

Older signals for AMRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Impax Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Health Pharmaceutical Pharmaceutical Industry Drugs Health Sciences Pharmaceuticals Policy Parkinson's Disease Treatment Of Parkinson's Disease Treatment Of Migraine Generic Drug Generic Products L Dopa Pharmaceutical Product
Is AMRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.4
52 Week Low 2.27
Average Volume 1,609,658
200-Day Moving Average 7.6403
50-Day Moving Average 3.0758
20-Day Moving Average 3.0645
10-Day Moving Average 3.076
Average True Range 0.2714
ADX 20.96
+DI 20.4338
-DI 25.4936
Chandelier Exit (Long, 3 ATRs ) 2.8217
Chandelier Exit (Short, 3 ATRs ) 3.3242
Upper Bollinger Band 3.5744
Lower Bollinger Band 2.5546
Percent B (%b) 0.09
BandWidth 33.277859
MACD Line -0.058
MACD Signal Line 0.0062
MACD Histogram -0.0643
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.82
Resistance 3 (R3) 2.82 2.78 2.79
Resistance 2 (R2) 2.78 2.73 2.77 2.78
Resistance 1 (R1) 2.71 2.71 2.69 2.71 2.77
Pivot Point 2.67 2.67 2.66 2.66 2.67
Support 1 (S1) 2.60 2.62 2.58 2.60 2.53
Support 2 (S2) 2.56 2.60 2.55 2.52
Support 3 (S3) 2.49 2.56 2.51
Support 4 (S4) 2.49